var data={"title":"Methacholine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Methacholine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6546?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=methacholine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Methacholine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709036\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Appropriate use:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Methacholine is a bronchoconstrictor agent for diagnostic purposes only and should not be used as a therapeutic agent. If a physician is performing the test, another person must be available in the building to give assistance if required; otherwise, a physician must be in the vicinity to be able to respond quickly. The patient must never be left unattended during the test. Methacholine challenge should be performed only under the supervision of a physician trained in and thoroughly familiar with all aspects of the technique of methacholine challenge, all contraindications, warnings and precautions, and the management of respiratory distress. Emergency equipment and medication should be immediately available to treat acute respiratory distress.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Bronchoconstriction:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Methacholine should be administered only by inhalation. Severe bronchoconstriction and reduction in respiratory function can result from the administration of methacholine. Patients with severe hyperreactivity of the airways can experience bronchoconstriction at a dosage as low as 0.025 mg/mL (0.125 cumulative units). If severe bronchoconstriction occurs, it should be reversed immediately by the administration of a rapid-acting inhaled bronchodilator agent (beta-agonist). Because of the potential for severe bronchoconstriction, methacholine challenge should not be performed in any patient with clinically apparent asthma, wheezing, or very low baseline pulmonary function tests (eg, FEV<sub>1</sub> less than 1 to 1.5 L or less than 70% of the predicted values). Please consult standard nomograms for predicted values.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193940\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Provocholine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193941\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Methacholine Omega;</li>\n      <li>Provocholine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193947\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Diagnostic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193942\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> For inhalation only mixed in solution; do not inhale powder.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bronchial airway hyperreactivity (diagnosis):</b> Inhalation: Before inhalation challenge, perform baseline pulmonary function tests; the patient must have an FEV<sub>1</sub> of at least 70% of the predicted value. Patients are given ascending serial concentrations (designated Vials E through A below) of methacholine starting with Vial E and ending with Vial A.  At each concentration, 5 breaths are administered via nebulizer (with dosimeter). The following is a suggested schedule for administration of methacholine challenge. Calculate cumulative units by multiplying number of breaths by concentration given. Total cumulative units is the sum of cumulative units for each concentration given. See following breakdown:</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Methacholine Administration Schedule</caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Vial</p></th>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Serial Concentration (mg/mL)</p></th>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Number of Breaths</p></th>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Cumulative Units per Concentration</p></th>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Total Cumulative Units</p></th></tr></thead>\n      <tbody>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">E</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">0.025</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">5</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">0.125</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">0.125</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">D</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">0.25</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">5</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">1.25</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">1.375</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">C</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">2.5</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">5</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">12.5</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">13.88</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">B</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">10</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">5</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">50</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">63.88</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">A</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">25</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">5</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">125</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">188.88</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;\">Determine FEV<sub>1</sub> within 5 minutes of challenge, a positive challenge is a 20% reduction in baseline FEV<sub>1</sub>. After challenge completion, an inhaled beta-agonist may be administered to expedite FEV<sub>1</sub> return to baseline and relieve patient discomfort.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6699693\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">Children &ge;5 years and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193943\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570381\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570382\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193930\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Inhalation, as chloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Provocholine: 100 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193920\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6699694\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer via inhalation only using a nebulizer with dosimeter. When transferring solution from each vial to nebulizer, use a sterile 0.22 micron filter. Give ascending serial concentrations (designated Vials E through A) of methacholine starting with Vial E and ending with Vial A.   At each of 5 inhalations of a serial concentration, the patient begins at functional residual capacity (FRC) and slowly and completely inhales the dose delivered. Within 5 minutes, FEV<sub>1</sub> values are determined. Further detailed instructions are available in the manufacturer&rsquo;s prescribing information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193931\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Bronchial airway hyperreactivity (diagnosis):</b> Diagnosis of bronchial airway hyperactivity in patients who do not have clinically apparent asthma.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193926\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Throat irritation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193934\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to methacholine, other parasympathomimetic agents, or any component of the formulation; repeat administration (other than on the day of challenge with increasing doses); coadministration with beta-adrenergic blocking agent </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193924\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bronchoconstriction: <b>[US Boxed Warning]: Administer only by inhalation; severe bronchoconstriction and reduction in respiratory function can result. Patients with severe hyperreactivity of the airways can experience bronchoconstriction at a dosage as low as 0.025 mg/mL (0.125 cumulative units). If severe bronchoconstriction occurs, reverse immediately by administration of a rapid-acting inhaled bronchodilator (beta-agonist).</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Risk to benefit: Evaluate risk to benefit in patients with cardiovascular disease accompanied by bradycardia, peptic ulcer disease, seizures, thyroid disease, urinary tract obstruction, vagotonia, or other condition that could be adversely affected by a cholinergic agent.  Use only if benefit outweighs risk in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease:  Guidelines contraindicate methacholine challenge testing in patients who have had a myocardial infarction (MI) or stroke within 3 months, uncontrolled hypertension (systolic &gt;200 mm Hg or diastolic &gt;100 mm Hg) or known aortic aneurysm. (Crapo [ATS] 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: <b>[US Boxed Warning]: Challenge should not be performed on any patient with clinically apparent asthma, wheezing, or very low baseline pulmonary function tests (eg, forced expiratory volume in the first second of expiration [FEV<sub>1</sub>] &lt;1 to 1.5 L or &lt;70% of the predicted values).</b>  Product should not be handled by persons with asthma or hay fever.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Females of childbearing potential: Administration should be within 10 days following the onset of menses or within 2 weeks of a negative pregnancy test.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: <b>[US Boxed Warning]: Methacholine is a bronchoconstrictor for diagnostic purposes only and should not be used as a therapeutic agent. <b>If a physician is performing the test, another person must be available in the building to give assistance if required; otherwise, a physician must be in the vicinity to be able to respond quickly. The patient must never be left unattended during the test</b>. Perform inhalation challenge under the supervision of a physician trained in and thoroughly familiar with all aspects of the technique, all contraindications, warnings, and precautions of methacholine challenge and the management of respiratory distress. Have emergency equipment and medication immediately available to treat acute respiratory distress.</b> For inhalation use only mixed in solution; do not inhale powder.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Inhalation study interpretation:  Use caution when interpreting inhalation study results. Methacholine challenge may occasionally be positive after influenza, upper respiratory tract infections or immunizations, in very young or very old patients, in patients with chronic lung disease (eg, cystic fibrosis, sarcoidosis, tuberculosis, chronic obstructive pulmonary disease [COPD]), allergic rhinitis without asthma, smokers, after exposure to air pollutants, or in patients who had had or will in the future develop asthma. Challenge testing has a greater negative predictive value (excluding asthma as a diagnosis) than positive predictive value (establishing an asthma diagnosis) (Crapo [ATS] 2000)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299681\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6221587\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9622&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May enhance the adverse/toxic effect of Cholinergic Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: May enhance the adverse/toxic effect of Methacholine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetropium: Cholinergic Agonists may diminish the anticholinergic effect of Cimetropium. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193928\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6699689\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Administration should be within 10 days following the onset of menses or within 2 weeks of a negative pregnancy test.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20616200\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if methacholine is excreted in breast milk. Breast-feeding is not recommended by the manufacturer. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28569144\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Forced expiratory volume in the first second of expiration (FEV<sub>1</sub>) at baseline ( &gt;1 to 1.5 L or &ge;70% of the predicted value) for females of childbearing potential, a negative pregnancy test within 2 weeks of methacholine challenge (or confirmation of menses within 10 days of challenge).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193923\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Methacholine, a cholinergic (parasympathomimetic) synthetic analogue of acetylcholine, stimulates muscarinic, postganglionic parasympathetic receptors, which results in smooth muscle contraction of the airways and increased tracheobronchial secretions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193933\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Duration: 30 to 45 minutes; 5 minutes if methacholine challenge is followed with a beta-agonist agent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323379\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Provocholine Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $63.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193935\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Kenbran (JP);</li>\n      <li>Provocholine (IL, JP);</li>\n      <li>Provokit (DE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Resp Crit Care Med. 2000;161(1):309-329. http://www.thoracic.org/statements/resources/pft/methacholine1-21.pdf10619836</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Provocholine (methacholine) [product monograph]. Brantford, Ontario, Canada: Methapharm Inc; September 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9622 Version 82.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709036\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F193940\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F193941\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F193947\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F193942\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F6699693\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F193943\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F16570381\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F16570382\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F193930\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F193920\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F6699694\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F193931\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F193926\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F193934\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F193924\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299681\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6221587\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F193928\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6699689\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20616200\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F28569144\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F193923\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F193933\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323379\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F193935\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9622|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=methacholine-patient-drug-information\" class=\"drug drug_patient\">Methacholine: Patient drug information</a></li></ul></div></div>","javascript":null}